CYGNOS BIOTECH, LLC — Department of Defense SBIR Phase II: THE PURPOSE OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II CONTRACT IS TO SHOW
CYGNOS BIOTECH, LLC — SBIR Phase II award from Department of Defense.
Phase II SBIR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $1,397,164 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Cygnos Biotech received $1.4 million from the Army to test whether its PVX Therapeutic can effectively treat viral infections. This Phase II project focuses on proving the treatment works for potential military health applications.
- Amount
- $1,397,164
- Agency
- Department of Defense · Department of the Army
- Program / Phase
- SBIR · Phase II
- NAICS
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- Place of performance
- FL
- Period
- 2026-02-02 → 2027-08-01
Technology domains
Description
THE PURPOSE OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II CONTRACT IS TO SHOW EFFICACY OF ANTI-VIRAL TREATMENT WITH THE PVX THERAPEUTIC.